Janus Henderson Group PLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,238,901 shares of the medical instruments supplier’s stock after acquiring an additional 28,064 shares during the quarter. Janus Henderson Group PLC owned about 0.54% of Becton, Dickinson and worth $242,760,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Koch Industries Inc. boosted its stake in shares of Becton, Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after purchasing an additional 1,395,182 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Becton, Dickinson and by 8.5% in the 2nd quarter. Vanguard Group Inc. now owns 17,255,948 shares of the medical instruments supplier’s stock valued at $3,366,809,000 after purchasing an additional 1,353,780 shares in the last quarter. Winslow Capital Management LLC acquired a new stake in shares of Becton, Dickinson and in the 2nd quarter valued at approximately $225,164,000. Parametric Portfolio Associates LLC boosted its stake in shares of Becton, Dickinson and by 216.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 1,320,259 shares of the medical instruments supplier’s stock valued at $257,596,000 after purchasing an additional 902,761 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. boosted its stake in shares of Becton, Dickinson and by 49,944.3% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 863,264 shares of the medical instruments supplier’s stock valued at $168,431,000 after purchasing an additional 861,539 shares in the last quarter. 88.60% of the stock is currently owned by institutional investors and hedge funds.

Several equities research analysts recently commented on the stock. Cowen reiterated a “buy” rating and set a $230.00 target price on shares of Becton, Dickinson and in a research report on Monday, August 14th. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research report on Monday, August 14th. Wells Fargo & Company reiterated a “positive” rating and set a $235.00 target price (up from $225.00) on shares of Becton, Dickinson and in a research report on Tuesday, October 24th. They noted that the move was a valuation call. Royal Bank Of Canada restated a “sector perform” rating and issued a $230.00 price target (up previously from $210.00) on shares of Becton, Dickinson and in a research report on Friday, November 3rd. Finally, Zacks Investment Research upgraded shares of Becton, Dickinson and from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. Four equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $217.08.

Becton, Dickinson and Company (NYSE BDX) opened at $219.68 on Monday. The company has a quick ratio of 5.03, a current ratio of 5.58 and a debt-to-equity ratio of 1.44. The firm has a market cap of $50,080.00, a PE ratio of 23.15, a P/E/G ratio of 1.72 and a beta of 1.06. Becton, Dickinson and Company has a fifty-two week low of $161.50 and a fifty-two week high of $229.68.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, November 2nd. The medical instruments supplier reported $2.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.37 by $0.03. The company had revenue of $3.17 billion for the quarter, compared to the consensus estimate of $3.14 billion. Becton, Dickinson and had a net margin of 8.52% and a return on equity of 20.56%. The firm’s quarterly revenue was down 2.0% on a year-over-year basis. During the same period in the previous year, the firm earned $2.12 EPS. analysts predict that Becton, Dickinson and Company will post 10.63 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be issued a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, December 7th. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.73. This represents a $3.00 annualized dividend and a yield of 1.37%. Becton, Dickinson and’s dividend payout ratio is 64.52%.

WARNING: “Janus Henderson Group PLC Acquires 28,064 Shares of Becton, Dickinson and Company (BDX)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/12/11/janus-henderson-group-plc-acquires-28064-shares-of-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.